Skip to main content

Cabaletta Bio, Inc.

CABA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001759138

No open-market purchases or sales by Cabaletta Bio, Inc. insiders were filed in the last 90 days; 139 institutions reported holding it in 13F filings for Q2 2026, worth $490.4M in total; no superinvestor holds it.

Q2 2021 vs. Q1 2021

How the institutions holding Cabaletta Bio, Inc. changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of CABA: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders6863−5
Shares16.2M15.8M−475.7K (−2.9%)
Value$180.1M$135.5M−$44.7M (−24.8%)

New holders (12)

Institutions that held Cabaletta Bio, Inc. at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to CABA in Q2 2021
InstitutionSharesValue% of portfolio
Ergoteles LLC56,000$482.0K0.01%
Tibra Equities Europe Ltd45,900$395.0K0.12%
HRT Financial LP37,371$321.0K0.00%
ExodusPoint Capital Management, LP33,857$291.0K0.00%
Renaissance Technologies LLC14,900$128.0K0.00%
PDT Partners, LLC14,400$124.0K0.01%
Alpine Global Management, LLC14,072$121.0K0.02%
Cubist Systematic Strategies, LLC13,928$120.0K0.00%
IHT Wealth Management, LLC13,215$114.0K0.01%
Point72 Hong Kong Ltd452$4.00K0.00%
Federated Hermes, Inc.126$1.00K0.00%
TCI Wealth Advisors, Inc.50$00.00%

Sold out (17)

Institutions that held Cabaletta Bio, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.